Organisation |
Areas of Interest |
Further Information |
|
|
This is a new funding opportunity of up to US $140 million, contingent upon availability of funds, for clinical trials with the aim to rapidly expand access to and confidence in COVID-19 vaccines by i) generating clinical evidence in special / sub-populations / age groups or ii) addressing clinical development gaps. Clinical trials which expand access and capacity in low- and middle-income countries (LMICs) are particularly encouraged. The Call for Proposals asks for an Expression of Interest (EOI) with a brief description of the current status of the project and a high-level Clinical Development Plan supporting initial emergency use approval / (conditional) licensure or similar. An outline of the proposed clinical trial and targeted label claims (supported by a study protocol synopsis), as well as regulatory and operational considerations for conduct of the clinical trial will be required. For clinical development gaps related to COVID-19 vaccines, please also see the report of the WHO consultation held 15 January 2021. Applicants should state in what positive ways the proposal can contribute to CEPI’s mission of increasing access to affordable vaccines to low- and middle-income countries, and if there is any willingness to support the provision of vaccine doses, as appropriate, via the COVAX facility. |
This Call is open for EOIs from January 28 2021 to May 28 2021. EOIs will be reviewed on a rolling basis. Details and How To Apply: Further information on the scope of funding, eligibility and application review criteria and application instructions are available in our Call Text (English, French, Spanish, Chinese, Japanese). Download our application form to submit an Express of Interest. CEPI reviews and evaluates proposals on their merits in the context of stated eligibility criteria, CEPI’s overall project portfolio and the equitable access benefits of the proposal. Regardless of eligibility at any stage of a funding Call, CEPI, in its sole discretion, reserves the right to consider and to decline any proposal. Technical and administrative questions about this Call should be directed to cfp@cepi.net |
|
Expression of interest. WHO and its partners are seeking to expand the capacity of low- and middle-income countries (LMICs) to produce COVID-19 vaccines and scale up manufacturing to increase global access to these critical tools to bring the pandemic under control. |
WHO will facilitate the establishment of one (or more, as appropriate) technology transfer hub(s) that will use a hub and spoke model (REF) to transfer a comprehensive technology package and provide appropriate training to interested manufacturers in LMICs. This initiative will initially prioritize the mRNA-vaccine technology but could expand to other technologies in the future. It is anticipated that WHO will work with funders and donors to mobilize financial support to establish the hubs and, as they are being established, to support the transfer of technology to selected manufacturers in LMICs, taking into consideration the need to establish permanent vaccine production capacity in regions where this is currently mostly absent. This broader objective will ensure that all WHO regions will be able to produce vaccines as essential preparedness measures against future infectious threats. To support this activity, we are seeking expressions of interest from:
|
For this initial expression of interest, entities willing to be considered as a technology transfer hub (as briefly described above under 1) or able to provide the necessary know-how, process training, and intellectual property rights (as briefly described above under 2), are invited to provide a brief summary of their capacity, and their interest in participating in the establishment of a COVID-19 vaccine technology transfer hub to: Martin Friede (friedem@who.int) and Raj Long (rlong@who.int) A call for interest from manufacturers in LMICs interested in receiving the technology developed by the technology transfer hub(s) will be issued by WHO in the coming weeks. Preference will be given to manufacturers of drugs, vaccines or active pharmaceutical substances based in LMICs and capable of producing medical products on a large scale under Good Manufacturing Practices. |
|
Apply for funding to support short term time-sensitive collection of data or samples or rapid turn-around research or analysis to either:
|
To apply you must be able to meet strict criteria, including, but not limited to:
Before applying, you should check the details of projects that are already funded to avoid duplicating existing work. You can also check our current priority areas to see what we think is important.
|
The maximum funding that may be sought is £80,000 (80% full economic cost) and includes any facilities costs. The usual duration will be 3 months, with a maximum of up to 6 months when necessary. Applicants must be based at research organisations eligible for UKRI funding. Business-led proposals are not eligible for this funding. Send your expression of interest as an email attachment to CV19researchinnovation@ukri.org. |
|
BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement. |
|
'If you are interested in partnering on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners! Submit a brief description and supporting materials through our CoronaWatch Portal.' |
The ability to undertake research should be equitable across the globe and we need to engage in all types of studies across all settings and care contexts.
The aim of this hub is to ensure that research teams can find the support, tools, resources and guidance that they need to aid their studies during this rapidly evolving situation. Using shared and open protocols and tools can raise research standards and enable easier and better data sharing.